Which trial do we need? A global, adaptive, platform trial to reduce death and disability from tuberculous meningitis
Authors:
Open Access
- 22 March 2023
- journal article
- editorial
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 29 (7) , 826-828
Abstract
No abstract availableKeywords
Funding Information
- Wellcome Trust
This publication has 17 references indexed in Scilit:
- UNITE4TB: a new consortium for clinical drug and regimen development for TBThe International Journal of Tuberculosis and Lung Disease, 2021
- Four-Month Rifapentine Regimens with or without Moxifloxacin for TuberculosisNew England Journal of Medicine, 2021
- Use of Infliximab to Treat Paradoxical Tuberculous Meningitis ReactionsOpen Forum Infectious Diseases, 2020
- Host Directed Therapies for Tuberculous MeningitisWellcome Open Research, 2020
- Treatment of Highly Drug-Resistant Pulmonary TuberculosisNew England Journal of Medicine, 2020
- Tuberculosis: progress and advances in development of new drugs, treatment regimens, and host-directed therapiesThe Lancet Infectious Diseases, 2018
- Tuberculous meningitisNature Reviews Neurology, 2017
- Intensified Antituberculosis Therapy in Adults with Tuberculous MeningitisNew England Journal of Medicine, 2016
- Randomized Pharmacokinetic and Pharmacodynamic Comparison of Fluoroquinolones for Tuberculous MeningitisAntimicrobial Agents and Chemotherapy, 2011
- Dexamethasone for the Treatment of Tuberculous Meningitis in Adolescents and AdultsNew England Journal of Medicine, 2004